Top Markets
#1 ORDI ORDI +75.07%
#2 tomiNet tomiNet +42.74%
#3 1000SATS (Ordinals) 1000SATS (Ordinals) +37.39%
#4 SATS (Ordinals) SATS (Ordinals) +36.77%
#5 pippin pippin +33.93%
#6 Axelar Axelar +33.55%
#7 Swarms Swarms +25.58%
#8 Bio Protocol Bio Protocol +23.17%
#9 Walrus Walrus +20.25%
#10 Zerebro Zerebro +20.22%
Coin of the day
ORDI ORDI
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rang in Aktien #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aktienkurs
$0.00047446
Marktkapitalisierung
$82.80
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Kategorie

Healthcare
P/B-Verhältnis für Neovacs S.A. (ALNEV)
P/B-Verhältnis zum April 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von Neovacs S.A. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0.00. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 16.05.
P/B-Verlauf für Neovacs S.A. von 2007 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 0.00 -100.00%
2024 9.86 -38.60%
2023 16.05 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6367 -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.0433 -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4872 -
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.7311 -
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.9706 -
NL